Publication:
A 19-Year Follow-Up of a Patient With Type 3 Ectrodactyly-Ectodermal Dysplasia-Clefting Syndrome Who Developed Non-Hodgkin Lymphoma

dc.authorscopusid7005672303
dc.authorscopusid12775739900
dc.authorscopusid40262205900
dc.authorscopusid7801557467
dc.authorscopusid6602955065
dc.authorscopusid7003347267
dc.contributor.authorBalcí, S.
dc.contributor.authorEngiz, O.
dc.contributor.authorOtken, G.
dc.contributor.authorSipahier, M.
dc.contributor.authorGürsu, G.
dc.contributor.authorKandemír, B.
dc.date.accessioned2020-06-21T14:55:01Z
dc.date.available2020-06-21T14:55:01Z
dc.date.issued2009
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Balcí] Sevim, Department of Clinical Genetics, Hacettepe Üniversitesi, Ankara, Turkey; [Engiz] Özlem, Department of Clinical Genetics, Hacettepe Üniversitesi, Ankara, Turkey; [Otken] Gulsen, Departments of Medical and Pediatric Genetics, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Sipahier] Murat, Faculty of Dentistry, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Gürsu] Giiler, Department of Plastic and Reconstructive Surgery, Hacettepe Üniversitesi, Ankara, Turkey; [Kandemír] Bedri, Department of Pathology, Ondokuz Mayis Üniversitesi, Samsun, Turkeyen_US
dc.description.abstractThe ectrodactyly-ectodermal dysplasia-clefting (EEC) syndrome is characterized by ectrodactyly, ectodermal dysplasia, and clefting. The development of a malignancy with EEC syndrome is very rare. Here we present follow-up on a Turkish boy with EEC syndrome type 3 who developed malignant lymphoma with high expression of p63. He had chronic renal failure due to recurrent urinary infections caused by ureterovesical reflux. Cervical, diffuse, large, B-cell non-Hodgkin lymphoma with high expression of p63 was diagnosed, and the patient died at 19 years of age. The transcription factor p63 is a key regulator of ectodermal, orofacial, and limb development. Mutations in the p63 gene can cause syndromes of ectodermal dysplasia, ectrodactyly, and orofacial clefting. Malignant lymphoma is a very rare complication of EEC syndrome. We suggest that p63 gene mutation analysis should be performed in every EEC syndrome patient with the possibility of developing malignant tumors. © 2009 Mosby, Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.tripleo.2009.04.043
dc.identifier.endpagee95en_US
dc.identifier.issn1079-2104
dc.identifier.issue3en_US
dc.identifier.pmid19716498
dc.identifier.scopus2-s2.0-69049116161
dc.identifier.startpagee91en_US
dc.identifier.urihttps://doi.org/10.1016/j.tripleo.2009.04.043
dc.identifier.volume108en_US
dc.identifier.wosWOS:000269361900051
dc.language.isoenen_US
dc.publisherMosby-Elsevieren_US
dc.relation.ispartofOral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodonticsen_US
dc.relation.journalOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleA 19-Year Follow-Up of a Patient With Type 3 Ectrodactyly-Ectodermal Dysplasia-Clefting Syndrome Who Developed Non-Hodgkin Lymphomaen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files